The invention relates to azaindole derivatives of general formula (I),
wherein X represents a group of general formula (X1).
Said compounds have a therapeutic potential in the treatment of diseases that are accompanied by an impaired dopamine metabolism and/or abnormal serotonin-5-HT1a signal transmission.
本发明涉及通式(I)的
吡唑吲衍
生物,其中X代表通式(X1)的一个基团。所述化合物在治疗伴随有受损的
多巴胺代谢和/或异常的5-羟
色胺-1a信号传递的疾病方面具有治疗潜力。